MET and non-small cell lung carcinoma: ,9 Broad next-generation sequencing for oncogenic alterations, including EGFR, ALK, KRAS, ROS-1, BRAF, NTRK, RET, MET exon 14 skipping, and ERBB (HER2), and other actionable drug targets are used to further tailor therapy in NSCLC.8